Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
13 studies found for:    "Hyperlipoproteinemia type 5"
Show Display Options
Rank Status Study
1 Terminated MK0859 Dose-Ranging Study (0859-003)
Conditions: Hypercholesterolemia;   Mixed Hyperlipemia
Intervention: Drug: MK0859
2 Completed
Has Results
Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients
Conditions: Hypertriglyceridemia;   Hyperlipoproteinemia Type IV;   Hyperlipoproteinemia Type V;   Hyperlipoproteinemia Type IIb;   Hyperlipidemia
Intervention: Drug: rosuvastatin
3 Withdrawn Efficacy Study of Daily Pro-Omega LDL for Low-Density Lipoprotein Cholesterol and Triglyceride Reduction
Condition: Mixed Hyperlipoproteinemia
Interventions: Dietary Supplement: Pro-Omega LDL;   Other: Placebo
4 Unknown  Comparison of the Efficacy and Safety of AtorVastatin mOnotherapy vs. Combination Atorvastatin/Fenofibric Acid
Condition: Mixed Hyperlipidemia
Interventions: Drug: Atorvastatin 10mg, fenofibric acid 135mg;   Drug: atorvastatin 20mg
5 Completed
Has Results
Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)
Condition: Mixed Hyperlipidemia
Interventions: Drug: MK-0524A;   Drug: Atorvastatin;   Drug: Simvastatin
6 Terminated Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin.
Condition: Mixed Hyperlipidemia
Interventions: Drug: torcetrapib/atorvastatin;   Drug: atorvastatin
7 Completed A Pilot Study to Evaluate the Lipid Effects of TRIA-662
Conditions: Hypertriglyceridemia;   Mixed Hyperlipidemia
Interventions: Drug: TRIA-662;   Drug: Placebo
8 Completed
Has Results
Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)
Conditions: Primary Hypercholesterolemia;   Mixed Hyperlipidemia
Interventions: Drug: SCH 900271 15mg;   Drug: SCH 900271;   Drug: Placebo
9 Completed Lipid Efficacy Study (0524B-022)(COMPLETED)
Conditions: Primary Hypercholesterolemia;   Mixed Hyperlipidemia
Interventions: Drug: niacin (+) laropiprant (+) simvastatin;   Drug: Comparator: niacin (+) laropiprant;   Drug: Comparator: simvastatin
10 Completed Lipid Efficacy/Tolerability Study (0524A-020)
Conditions: Primary Hypercholesterolaemia;   Mixed Hyperlipidaemia
Interventions: Drug: niacin (+) laropiprant;   Drug: ER-niacin
11 Completed A Study to Evaluate an Investigational Drug in Patients With Mixed Hyperlipidemia (0653A-071)(COMPLETED)
Conditions: Hyperlipidemia;   Hypercholesterolemia;   Hypertriglyceridemia
Intervention: Drug: ezetimibe (+) simvastatin
12 Completed Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED)
Conditions: Hypercholesterolemia;   Hypertriglyceridemia
Interventions: Drug: MK0653, ezetimibe;   Drug: Comparator: fenofibrate monotherapy
13 Completed Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036)
Conditions: Hypercholesterolemia;   Hypertriglyceridemia
Interventions: Drug: MK0653, ezetimibe;   Drug: Comparator: fenofibrate monotherapy

Study has passed its completion date and status has not been verified in more than two years.